R&D | October 29, 2025
Orion secures license to Abzena’s next-generation cancer antibody
The antibody was designed and developed at Abzena’s Cambridge, UK,
The antibody was designed and developed at Abzena’s Cambridge, UK,
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Expanding US operations to address the increased demand for API development and manufacturing
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
Subscribe To Our Newsletter & Stay Updated
